MB
MBXBF.US Microbix Biosystems Inc.
- Market cap
- USD 27.8M
- P/E
- -
- P/B
- 1.63x
- ROE
- -18.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is MBXBF.US undervalued?
Graham numberThe Graham number of Microbix Biosystems Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Microbix Biosystems Inc. fundamental analysis
No fundamental analysis for Microbix Biosystems Inc. yet.
Microbix Biosystems Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under …
Full company profileMicrobix Biosystems Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Microbix Biosystems Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.52M | 10.2M | 12.5M | 13.4M | 10.5M | 18.6M | 19.1M | 16.5M | 25.4M | 18.6M | 15.5M |
| Gross Profit | 4.98M | 4.81M | 5.37M | 6.55M | 4.66M | 11.0M | 11.1M | 7.48M | 15.4M | 9.85M | 7.40M |
| Operating Income | 839K | -575K | 109K | 1.11M | -525K | 4.84M | 2.61M | -2.74M | 3.90M | -1.58M | -3.83M |
| EBITDA | - | -2.80M | -7.08M | 1.68M | -2.91M | 5.66M | 3.73M | 1.96M | 6.21M | 428K | -1.66M |
| Net Income | 748K | -3.78M | -8.62M | 31.9K | -6.23M | 3.23M | 1.79M | -39.5K | 3.52M | -2.25M | -4.54M |
| EPS | - | -0.04 | -0.09 | 0.00 | -0.06 | 0.03 | 0.01 | 0.00 | 0.03 | -0.02 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 25.2M | 26.4M | 19.3M | 19.6M | 15.6M | 28.8M | 33.1M | 35.7M | 38.1M | 37.4M | 34.1M |
| Total Liabilities | 9.96M | 11.3M | 8.96M | 9.09M | 8.98M | 10.3M | 8.21M | 11.0M | 9.80M | 9.62M | 9.80M |
| Shareholders' Equity | 15.3M | 15.2M | 10.4M | 10.5M | 6.62M | 18.6M | 24.9M | 24.6M | 28.3M | 27.8M | 24.3M |
| Cash & Short-term Investments | 5.42K | 54.5K | 44.4K | 95.6K | 92.7K | 9.99M | 13.5M | 11.6M | 13.0M | 12.1M | 7.16M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 913K | 297K | -537K | 44.4K | 8.57K | 2.11M | 3.47M | -1.09M | 4.35M | -80.3K | -4.50M |
| Capital Expenditure | 1.64M | 182K | 944K | 433K | 813K | 1.24M | 2.03M | 1.02M | 1.91M | 797K | 588K |
| Free Cash Flow | - | -344K | -1.76M | -470K | -805K | 804K | 1.44M | -2.11M | 2.44M | -878K | -5.09M |
| Ratios | |||||||||||
| ROE | 4.9% | -24.9% | -83.3% | 0.3% | -94.1% | 17.4% | 7.2% | -0.2% | 12.4% | -8.1% | -18.7% |
| ROA | 3.0% | -14.3% | -44.6% | 0.2% | -39.9% | 11.2% | 5.4% | -0.1% | 9.2% | -6.0% | -13.3% |
| Net Profit Margin | 7.9% | -37.1% | -68.9% | 0.2% | -59.2% | 17.4% | 9.4% | -0.2% | 13.9% | -12.1% | -29.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Microbix Biosystems Inc. dividends
Microbix Biosystems Inc. has not paid dividends in the last 9 fiscal years.
Who owns Microbix Biosystems Inc.
- Insiders 14.93%
- Institutions 0.00%
- Public & others 85.07%
- Shares outstanding 137M
- Free float 114M
Microbix Biosystems Inc. company profile
- Company name
- Microbix Biosystems Inc.
- Ticker
- MBXBF.US
- ISIN
- CA59501P1045
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- 265 Watline Avenue, Mississauga, ON, Canada, L4Z 1P3
- Phone
- 905 361 8910
- Website
- microbix.com
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Microbix Biosystems Inc. management
6- Mr. Cameron L. GroomePresident, CEO & Director
- Mr. James S. CurrieChief Financial Officer
- Dr. Kenneth Hughes Ph.D.Chief Operating Officer
- Mr. Phillip CasselliSenior Vice President of Sales & Business Development
- Dr. Mark Luscher Ph.D.Senior Vice President of Scientific Affairs
- Mr. Christopher B. LobbCompliance Officer, General Counsel & Secretary